OLD Category: signatures

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

• Karube K. et al.,

An unusual combination of mirror-image dextrocardia with familial medulloblastoma : Is there a histogenetic relationship?

• Ke C. et al.,

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy

• Castellanos EH, Feld E, Estrada MV, Sanders ME, Massion PP, Johnson DB, Balko JM, Horn L

Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study

• Cascione L. et al.,

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

• Prat A, Navarro A, Paré L, Reguart N, Victoria I , Viñolas N, Vivancos A, Arance A, Felip E

Medulloblastoma with tri-vergent melanocytic, myogenic and cartiligious elements

• Chua F.H.Z. et al.,

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies

• Scott D.W. et al.,

Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression

• Stricker T.P. et al.,

Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm

• Yoon N. et al.,

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine

• Bayani J. et al.,

Lymphoma cell-of–origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts

• Gifford G. et al.,

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition

• Nakagawa S. et al.,